Comments

Kezar Life Sciences Analyst Ratings

KZRNASDAQ
Logo brought to you by Benzinga Data
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$5.64
-0.52-8.44%
At close: -
$5.55
-0.09-1.60%
After Hours: 9:28 AM EDT
Q4 2024 earnings were released today after the market close
Kezar Life Sciences (KZR) ForecastNewsEarningsKezar Life Sciences (KZR) OptionsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Equal-Weight
Highest Price Target1
$9.00
Lowest Price Target1
$9.00
Consensus Price Target1
$9.00

Kezar Life Sciences Analyst Ratings and Price Targets | NASDAQ:KZR | Benzinga

Kezar Life Sciences Inc has a consensus price target of $9 based on the ratings of 4 analysts. The high is $9 issued by Wells Fargo on December 19, 2024. The low is $9 issued by Wells Fargo on December 19, 2024. The 3 most-recent analyst ratings were released by Wells Fargo, Wells Fargo, and HC Wainwright & Co. on December 19, 2024, November 14, 2024, and August 14, 2024, respectively. With an average price target of $9 between Wells Fargo, Wells Fargo, and HC Wainwright & Co., there's an implied 62.16% upside for Kezar Life Sciences Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
3
Oct 24
1
Nov 24
2
Dec 24
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Wells Fargo

1calculated from analyst ratings

Analyst Ratings for Kezar Life Sciences

Buy NowGet Alert
12/19/2024Buy Now62.16%Wells Fargo
Derek Archila59%
$11 → $9MaintainsEqual-WeightGet Alert
12/02/2024Buy Now—HC Wainwright & Co.
Raghuram Selvaraju43%
—ReiteratesNeutral → NeutralGet Alert
11/14/2024Buy Now98.2%Wells Fargo
Derek Archila59%
$20 → $11MaintainsEqual-WeightGet Alert
10/18/2024Buy Now—HC Wainwright & Co.
Raghuram Selvaraju43%
—Reiterates → NeutralGet Alert
10/14/2024Buy Now—HC Wainwright & Co.
Raghuram Selvaraju43%
—Reiterates → NeutralGet Alert
10/02/2024Buy Now—HC Wainwright & Co.
Raghuram Selvaraju43%
—DowngradeBuy → NeutralGet Alert
08/14/2024Buy Now26.13%HC Wainwright & Co.
Raghuram Selvaraju43%
$70 → $70ReiteratesBuy → BuyGet Alert
07/22/2024Buy Now26.13%HC Wainwright & Co.
Raghuram Selvaraju43%
$200 → $70MaintainsBuyGet Alert
05/10/2024Buy Now260.36%HC Wainwright & Co.
Raghuram Selvaraju43%
$200 → $200ReiteratesBuy → BuyGet Alert
03/15/2024Buy Now260.36%HC Wainwright & Co.
Raghuram Selvaraju43%
$200 → $200ReiteratesBuy → BuyGet Alert
12/04/2023Buy Now260.36%HC Wainwright & Co.
Raghuram Selvaraju43%
 → $200ReiteratesBuy → BuyGet Alert
11/27/2023Buy Now260.36%HC Wainwright & Co.
Raghuram Selvaraju43%
 → $200ReiteratesBuy → BuyGet Alert
11/14/2023Buy Now-63.96%Wells Fargo
Derek Archila59%
$40 → $20MaintainsEqual-WeightGet Alert
10/12/2023Buy Now260.36%HC Wainwright & Co.
Raghuram Selvaraju43%
 → $200ReiteratesBuy → BuyGet Alert
10/05/2023Buy Now—JonesTrading
Catherine Novack28%
—DowngradeBuy → HoldGet Alert
09/25/2023Buy Now260.36%HC Wainwright & Co.
Raghuram Selvaraju43%
$180 → $200MaintainsBuyGet Alert
08/11/2023Buy Now—Wells Fargo
Derek Archila59%
—DowngradeOverweight → Equal-WeightGet Alert
08/11/2023Buy Now224.32%HC Wainwright & Co.
Raghuram Selvaraju43%
$190 → $180MaintainsBuyGet Alert
05/12/2023Buy Now242.34%HC Wainwright & Co.
Raghuram Selvaraju43%
$210 → $190MaintainsBuyGet Alert
05/12/2023Buy Now134.23%Wells Fargo
Derek Archila59%
$140 → $130MaintainsOverweightGet Alert
03/16/2023Buy Now—William Blair
Matt Phipps22%
—DowngradeOutperform → Market PerformGet Alert
03/16/2023Buy Now278.38%HC Wainwright & Co.
Raghuram Selvaraju43%
 → $210Reiterates → BuyGet Alert
01/03/2023Buy Now152.25%Wells Fargo
Derek Archila59%
$170 → $140MaintainsOverweightGet Alert
08/12/2022Buy Now278.38%HC Wainwright & Co.
Raghuram Selvaraju43%
$200 → $210MaintainsBuyGet Alert
06/28/2022Buy Now206.31%Wells Fargo
Derek Archila59%
$130 → $170MaintainsOverweightGet Alert
05/13/2022Buy Now134.23%Wells Fargo
Derek Archila59%
$140 → $130MaintainsOverweightGet Alert
05/04/2022Buy Now152.25%Wells Fargo
Derek Archila59%
$190 → $140MaintainsOverweightGet Alert

FAQ

Q

What is the target price for Kezar Life Sciences (KZR) stock?

A

The latest price target for Kezar Life Sciences (NASDAQ:KZR) was reported by Wells Fargo on December 19, 2024. The analyst firm set a price target for $9.00 expecting KZR to rise to within 12 months (a possible 62.16% upside). 9 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Kezar Life Sciences (KZR)?

A

The latest analyst rating for Kezar Life Sciences (NASDAQ:KZR) was provided by Wells Fargo, and Kezar Life Sciences maintained their equal-weight rating.

Q

When was the last upgrade for Kezar Life Sciences (KZR)?

A

There is no last upgrade for Kezar Life Sciences

Q

When was the last downgrade for Kezar Life Sciences (KZR)?

A

The last downgrade for Kezar Life Sciences Inc happened on October 2, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Kezar Life Sciences Inc.

Q

When is the next analyst rating going to be posted or updated for Kezar Life Sciences (KZR)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kezar Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kezar Life Sciences was filed on December 19, 2024 so you should expect the next rating to be made available sometime around December 19, 2025.

Q

Is the Analyst Rating Kezar Life Sciences (KZR) correct?

A

While ratings are subjective and will change, the latest Kezar Life Sciences (KZR) rating was a maintained with a price target of $11.00 to $9.00. The current price Kezar Life Sciences (KZR) is trading at is $5.55, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved